Funding

[Funding alert] Cambridge-based Apollo Therapeutics Secures USD 33.5M in a Second close of its Series C Round Funding

Jan 2, 2024 | By Startup Rise EU

Apollo Therapeutics, a Cambridge, Massachusetts-based company, closed its Series C round of funding with USD 33.5 million. Patient Square Capital led the $260 million round, in which several new investors, including M&G plc and two of the biggest US public pension plans, joined forces with existing investors, including Rock Springs Capital.

Apollo Therapeutics, a Cambridge, Massachusetts-based company, closed its Series C round of funding with USD 33.5 million. Patient Square Capital led the $260 million round, in which several new investors, including M&G plc and two of the biggest US public pension plans, joined forces with existing investors, including Rock Springs Capital.

The company plans to use the funds to licence or purchase more clinical stage programmes that satisfy stringent selection criteria, advance pipeline programmes through clinical development, and further fund its drug discovery and development activities based on advances in basic medical research made at its partner institutions.

Read also - London-based Olsam Group Acquired Dwarfs

Apollo Therapeutics is a portfolio biopharmaceutical company led by Dr. Richard Mason, the CEO, that focuses on turning basic medical research into pharmaceuticals.

RECOMMENDED FOR YOU

recomd
Acquisition
Visma acquisiton news – Osla-based Visma has Acquired Moj eRačun
Startup Rise EU
Jul 8, 2024
recomd
Spain
[Funding alert] Barcelona-based Workfully Secures €1.2 million in Seed Funding
Startup Rise EU
Oct 11, 2023
recomd
Funding
[Funding alert] Amsterdam-based Femcare Startup Yoni Secures €2.3M in Funding
Startup Rise EU
Dec 18, 2023

A centralised management team of capital allocators and functional leaders with extensive backgrounds in pharmaceutical R&D, manufacturing, commercial strategy, fund-raising, and business development forms the foundation of the portfolio-model. This team is then leveraged over a wide range of therapeutic programmes, each of which is overseen by an experienced and committed asset leader.

Read also - GLORY to Acquire Flooid

About Apollo Therapeutics

Apollo Therapeutics, As a portfolio biotech, they generate value for our investors, patients, and inventors by working on a wide range of drug programmes. Their goal is to create a diverse clinical-stage portfolio of assets with a concentration on high-value markets. In their three main biological focus areas—immunology, cell stress response, and cell signaling—they offer more than 20 programmes.

Recommended Stories for You

story
Funding

Helsing funding news – Germany-based Helsing Secures €450 Million in a Series C Round Funding

Startup Rise EU Jul 12, 2024

story
Funding

[Funding alert] Milan-based Fintech Startup Qomodo Secures €34.5 Million in Funding

Startup Rise EU Nov 7, 2023

story
Funding

[Funding alert] Vienna-based WeAreDevelopers Secures a 7-figure Investment

Startup Rise EU Apr 8, 2024

story
Funding

[Funding alert] Barcelona-based Domma Secures €950k in Funding

Startup Rise EU Feb 6, 2024

story
Spain

[Funding alert] Barcelona-based Delfos Secures €6.3 Million in Seed Funding

Startup Rise EU Jan 17, 2024

story
Funding

[Funding alert] Hamburg-based foodtech Startup GoodBytz Raises €12 million in Series A Round Funding

Startup Rise EU Oct 24, 2023